Amyloidosis Foundation

09/04/2026

ONLY 4 DAYS LEFT!!!!!
to register to participate in the Annual Amyloidosis Foundation Run, Walk, Bike, Roll 🏃‍➡️👩‍🦽‍➡️

Whether you run, walk, bike, or roll — every step and every mile helps bring hope to patients and families facing this disease.
📅 Event Dates: June 1 – September 8
🌎 Participate virtually from anywhere
💜 Support awareness, education, and research
Register today and invite your friends, family, and coworkers to join your team!
Click here 👉🏼

Walk or run or bike at your leisure to help raise awareness of amyloidosis, in your local park, or your neighborhood. Encourage your family and friends to register and participate.

09/02/2026

This article is about a personal medical journey which involves a four-year-long search to solve a problem which I hope will be an inspiration to those who read it.

The title comes from a grand rounds lecture given by Dr. Justin Grodin, a faculty member in advanced heart failure and cardiac amyloidosis at UT Southwestern. As the old saying goes, “When you hear hoofbeats you think of horses, but occasionally there is a zebra in the herd.” Well, my zebra is cardiac amyloidosis. When I was in medical school, this disease was hardly mentioned. Most doctors knew little to nothing about it.
click below to read the article.

Feature Article By David M. Lavine, MD This article was originally published in the July/August 2026 issue of  Tarrant County Physician. This article is about a personal medical…

09/01/2026

✨TOMORROW'S SESSION ✨
Wednesday, September 2, 6:00 PM – 7:00 PM America/New_York

Treatment for AL amyloidosis continues to evolve. Learn how Dr. Dispenzieri incorporates emerging therapies into patient care, the latest advances in treatment, and what these developments may mean for patient outcomes. Gain insight into how new treatment options are shaping the future of AL amyloidosis care.

To Register: https://us06web.zoom.us/meeting/register/aiSE6JNTQZW9iFDpWruhPg
Zoom Meeting ID: 89859543905

08/30/2026

No added cardiovascular benefit of eplontersen on top of standard care for ATTR-CM

Key takeaways:
-CARDIO-TTRansform is the largest trial in patients with ATTR-CM to date.
-Eplontersen did not provide CV benefit compared with placebo, especially in patients already on a stabilizer.
READ THE FULL ARTICLE HERE 👇🏼

MUNICH — In patients with transthyretin amyloidosis with cardiomyopathy, once-monthly eplontersen, in addition to current standard treatments, did not lower risk for death from CV causes and recurrent CV events compared with placebo.Results of CARDIO-TTRansform, the largest trial in patients w...

08/28/2026

The Amyloidosis Run, Walk, Bike & Roll is coming to an end soon! 💜

There’s still time to join us and make a difference in the fight against amyloidosis! The Amyloidosis Foundation’s Run, Walk, Bike & Roll event ends September 8.

Whether you run, walk, bike, or roll, every step and every mile helps raise awareness, support patients and families, and advance the mission of the Amyloidosis Foundation.

📅 Event ends: September 8
🚶‍♀️🏃‍♂️🚴‍♀️♿ Run • Walk • Bike • Roll
💜 Every mile matters. Every person makes a difference.

Don’t miss your chance to participate and show your support for the amyloidosis community! 💜
REGISTER HERE ⬇️
https://bit.ly/2026VirtualWalk

08/27/2026

Heart imaging plays a key role in finding cardiac amyloidosis early, determining how serious it is, and monitoring whether treatment is working. Doctors get the best picture by combining imaging results with blood tests and other clinical information.

Doctors use several types of heart imaging to detect and monitor cardiac amyloidosis. Echocardiograms can raise suspicion, specialized scans can help confirm the type, and cardiac MRI can show how much amyloid is affecting the heart and whether treatment is working. Newer scans may provide even more information, but they still need further study.
READ THE DETAILED STUDY HERE 👇🏼
Imaging Cardiac Amyloidosis: From Early Diagnosis to Risk Stratification and Evaluation of Treatment Efficacy

Cardiac amyloidosis (CA) is an infiltrative cardiomyopathy caused by extracellular deposition of misfolded proteins, most commonly immunoglobulin light chains (AL) or transthyretin (ATTR). Once considered a rare disease, CA is increasingly recognised due to improved diagnostic strategies and the ava...

08/25/2026

✨TOMORROW'S SESSION ✨
Wednesday, August 26, 6:00 PM – 7:00 PM America/New_York

Learn how cardiac testing can help detect and monitor heart involvement in amyloidosis. We will explain common tests, what to expect, and how results may guide care, with time for patient and caregiver questions.

Dr. Hasan Siddiqi, MD, MSCR, FACC
Hasan Siddiqi MD, MSCR, FACC is an advanced heart failure cardiologist and directs its cardiac amyloidosis program. He manages amyloidosis, heart failure, VAD, and transplant patients in the world's largest heart transplant center, leads research and trials, and trained at Harvard, Michigan, Penn, and Brigham.

To Register: https://us06web.zoom.us/meeting/register/AZDwB7PuTKmWDWoW1P_Dzg
Zoom Meeting ID: 81845030592

08/23/2026

The Amyloidosis Patient Journey:
From New Diagnosis to Patient Empowerment Half-Day Conference

Saturday, Sept. 19, 2026
8:30 – 2:00 pm ET
Location: Alumni Center, Northeastern University, Boston, MA

The Society of Participatory Medicine hosts regular conferences throughout the year to help empower patients & healthcare professionals. March 20, 2025.

08/22/2026

Monitoring ATTR-CM Over Time

ATTR-CM requires regular monitoring to track heart health, disease progression, and treatment effectiveness through imaging, blood tests, functional assessments, and symptom tracking. Routine follow-ups help doctors identify changes early and adjust treatment when needed.
READ MORE HERE 👇🏼

Monitoring ATTR-CM over time helps doctors track disease progression, assess treatment effectiveness, and understand your long-term outlook

08/21/2026

TIME IS "RUNNING" OUT
💜 Amyloidosis Foundation’s Virtual Run • Walk • Bike • Roll! 💜

Until September 8, you can move your way to help raise awareness and support for those affected by amyloidosis. Whether you run, walk, bike, or roll — every mile makes a difference!

✅ Participate from anywhere
✅ Set your own pace and goals
✅ Support patients, families, education, and research
✅ Share your journey and inspire others

Together, we can bring hope, awareness, and progress to the amyloidosis community.
Register today: https://bit.ly/2026VirtualWalk